Receptor Conversion between Primary Tumors and Distant Metastases in 121 Cases of Metastatic Breast Cancer

Chaoying Wang, Lijun Di, Kun Yan, Huiping Li, Guohong Song, Hanfang Jiang, Shanshan Yin, Xu Liang, Ying Yan, Bin Shao, Fengling Wan, Jun Ren

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Ultrasound, Peking University Cancer Hospital and Institute, Beijing, China.

DOI: 10.4236/ijcm.2013.42020                

Abstract

The article published in Vol.4 No.2 102-107, 2013 has been withdrawn by the authors for further revision. This paper will be re-submitted to IJCM after the authors revise it.

Keywords

Breast Cancer; Receptor Conversion; Estrogen Receptor; Progesterone Receptor; HER2

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	F. Bray, P. McCarron and D. M. Parkin, “The Changing Global Patterns of Female Breast Cancer Incidence and Mortality,” Breast Cancer Research, Vol. 6, No. 6, 2004, pp. 229 239. doi:10.1186/bcr932
[2]	L. D. Hoefnagel, M. J. van de Vijver, H. J. van Slooten, P. Wesseling, J. Wesseling and P. J. Westenend, “Receptor Conversion in Distant Breast Cancer Metastases,” Breast Cancer Research, Vol. 12, No. 5, 2010, p. R75.
[3]	D. F. Hull, G. M. Clark, C. K. Osborne, G. C. Chamness, W. A. Knight and W. L. McGuire, “Multiple Estrogen Receptor Assays in Human Breast Cancer,” Cancer Re search, Vol. 43, No. 1, 1983, pp. 413 416.
[4]	D. Gancberg, A. Di Leo, F. Cardoso, G. Rouas, M. Ped rocchi, A. Paesmans M. Verhest, C. Bernard Marty, M. J. Piccart and D. Larsimont, “Comparison of HER 2 Status between Primary Breast Cancer and Corresponding Dis tant Metastatic Sites,” Annals of Oncology, Vol. 13, No. 7, 2002, pp. 1036 1043. doi:10.1093/annonc/mdf252
[5]	K. C. Lear Kaul, H. R. Yoon, B. K. Kleinschmidt De Masters, L. McGavran and M. Singh, “Her 2/Neu Status in Breast Cancer Metastases to the Central Nervous Sys tem,” Archives of Pathology & Laboratory Medicine, Vol. 127, No. 11, 2003, pp. 1451 1457.
[6]	Y. Gong, D. J. Booser and N. Sneige, “Comparison of HER 2 Status Determined by Fluorescence in Situ Hy bridization in Primary and Metastatic Breast Carcinoma,” Cancer, Vol. 103, No. 9, 2005, pp. 1763 1769. doi:10.1002/cncr.20987
[7]	J. Zidan, I. Dashkovsky, C. Stayerman, W. Basher, C. Cozacov and A. Hadary, “Comparison of HER 2 Over expression in Primary Breast Cancer and Metastatic Sites and Its Effect on Biological Targeting Therapy of Metas tatic Disease,” British Journal of Cancer, Vol. 93, No. 5, 2005, pp. 552 556. doi:10.1038/sj.bjc.6602738
[8]	C. X. Zhu and Y. Jin, “Clinical Significance of Ultra sound Guided Biopsy in Detecting the Expressions of ER, PR and CerbB 2 in Brest Carcinoma,” Journal of Medical Imaging, Vol. 22, No. 1, 2012, pp. 68 70.
[9]	Z. F. Jiang, Y. H. Xu, S. Q. Song and Y. Sun, “Consensus of Endocrinotherapy for Breast Cancer,” Chinese Journal of Oncology, Vol. 28, No. 3, 2006, pp. 238 239.
[10]	E. E. Lower, E. L. Glass, D. A. Bradley, R. Blau and S. Heffelfinger, “Impact of Metastatic Estrogen Receptor and Progesterone Receptor Status on Survival,” Breast Cancer Research and Treatment, Vol. 90, No. 1, 2005, pp. 65 70. doi:10.1007/s10549 004 2756 z
[11]	C. Liedtke, K. Broglio, S. Moulder, L. Hsu, S. W. Kau and W. F. Symmans, “Prognostic Impact of Discordance between Triple Receptor Measurements in Primary and Recurrent Breast Cancer,” Annals of Oncology, Vol. 20, No. 12, 2009, pp. 1953 1958. doi:10.1093/annonc/mdp263
[12]	M. E. Hammond, D. F. Hayes, M. Dowsett, D. C. Allred, K. L. Hagerty and S. Badve, “American Society of Clini cal Oncology/College of American Pathologists Guide line Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Can cer,” Journal of Clinical Oncology, Vol. 28, No. 16, 2010, pp. 2784 2795. doi:10.1200/JCO.2009.25.6529
[13]	C. Simmons, N. Miller, W. Geddie, D. Giunfelice, M. Oldfield and G. Dranitsaris, “Does Confirmatory Tumor Biopsy Alter the Management of Breast Cancer Patients with Distant Metastases?” Annals of Oncology, Vol. 20, No. 9, 2009, pp. 1499 1504. doi:10.1093/annonc/mdp028
[14]	X. Cui, R. Schiff, G. Arpino, C. K. Osborne and A. V. Lee, “Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy,” Jour nal of Clinical Oncology, Vol. 23, No. 30, 2005, pp. 7721 7735. doi:10.1200/JCO.2005.09.004
[15]	E. E. Lower, E. Glass, R. Blau and S. Harman, “HER 2/ Neu Expression in Primary and Metastatic Breast Can cer,” Breast Cancer Research and Treatment, Vol. 113, No. 2, 2009, pp. 301 306. doi:10.1007/s10549 008 9931 6
[16]	L. M. Bender and R. Nahta, “HER2 Cross Talk and The rapeutic Resistance in Breast Cancer,” Frontiers in Bio science, Vol. 13, 2009, pp. 3906 3912.
[17]	M. Cassatella, L. Zorzino and M. Sandri, “Single Circu lating Tumor Cell Profiling: A New Perspective for Tar geted Therapy?” Future Oncology, Vol. 8, No. 10, 2012, pp. 1253 1256. doi:10.2217/fon.12.119